Online inquiry

IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15085MR)

This product GTTS-WQ15085MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNC gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_002160.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3371
UniProt ID P24821
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15085MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2759MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG162
GTTS-WQ15136MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SYNT-001
GTTS-WQ14352MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ1281MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-414
GTTS-WQ10524MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ8632MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ15741MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ6176MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CP-751871
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW